

Supplementary materials: New Organometallic Ru(II) Compounds with Lonidamine Motif as Antitumor Agents

Ilya A. Shutkov, Yulia N. Okulova, Dmitrii M. Mazur, Nikolai A. Melnichuk, Denis A. Babkov, Elena V. Sokolova, Alexander A. Spasov, Elena R. Milaeva and Alexey A. Nazarov




Figure S1. Experimental spectrum for complex 15, simulated spectrum for $[M+H]^+$, simulated spectrum for $[M+Na]^+$.




Figure S2. Experimental spectrum for complex **16**, simulated spectrum for $[M+H]^+$, simulated spectrum for $[M+Na]^+$.




Figure S3. Experimental spectrum for complex 17, simulated spectrum for $[M+H]^+$, simulated spectrum for $[M+Na]^+$.




Figure S4. Experimental spectrum for complex 18, simulated spectrum for $[M-Cl]^+$.





Figure S5. Experimental spectrum for complex **19**, simulated spectrum for [M-Cl]⁺.




Figure S6. Signal shifts in ^1H NMR spectra of ligand **5** and complexes **11**, **14**.